Lp(a)

What Lp(a) Measures

Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) attached. Genetically determined - your level is set by ~age 5 and doesn't change meaningfully with lifestyle. About 20% of the population has elevated Lp(a) (>50 mg/dL), which carries 2–4× higher cardiovascular risk independent of LDL or ApoB.

Because it's fixed for life, you only need to test once. If elevated, the answer isn't "lower Lp(a)" (we have no good tools for that yet - though pelacarsen is in late-stage trials) - it's "be more aggressive with everything else": lower ApoB harder, blood pressure tighter, lifestyle dialed.

What Affects This Biomarker

Lp(a) is influenced by: genetics (~80–90% of variance - this is the dominant factor), kidney disease (raises modestly), pregnancy (raises), menopause (raises), hypothyroidism (raises), and very few pharmacologic agents shift it - statins barely budge it; PCSK9 inhibitors lower modestly (~25%); niacin lowers ~25%; in trials, pelacarsen and olpasiran (antisense / siRNA against apo(a)) lower 70–95% but aren't approved yet.

In the Context of Peptide Protocols

Test Lp(a) once at baseline. If <30 mg/dL: never test again, don't worry about it. If 30–75: aggressive lifestyle + tight ApoB target. If >75: discuss aggressive pharmacologic management with your cardiologist. Doesn't move with peptide protocols. The CV outcomes data on the new RNA-based therapies is the biggest story to watch in this space.

Deep Dive

What Lp(a) really is, and why it carries a triple threat

Lp(a) is usually described as "LDL with an extra protein," but that undersells why it is uniquely dangerous. The particle is a standard ApoB-100 lipoprotein with a second protein, apolipoprotein(a), covalently bound on top. Apo(a) is encoded by the LPA gene and is structurally homologous to plasminogen, the precursor of the enzyme that dissolves clots. That single structural fact is why Lp(a) is thought to be atherogenic and prothrombotic at the same time. It deposits cholesterol into the arterial wall like any ApoB particle, while its plasminogen-mimicking tail may blunt normal clot breakdown (fibrinolysis).

Lp(a) is also the main carrier of oxidized phospholipids in human plasma, which makes it strongly pro-inflammatory inside the vessel wall. So a single elevated Lp(a) particle contributes to three problems at once: plaque, clotting, and inflammation. That is the mechanistic reason its risk is not simply "more LDL."

Why the units on your lab report matter more than the number

This is the single most common Lp(a) testing mistake. The LPA gene contains a variable number of repeated segments called kringle IV type 2 (KIV-2). People carry anywhere from a couple to more than 40 copies, and copy number determines the physical size of the apo(a) protein. Fewer repeats generally means a smaller isoform and a higher plasma concentration.

That size variability breaks mass-based assays. When Lp(a) is reported in **mg/dL**, the assay estimates total apo(a) mass, which is distorted by isoform size. When it is reported in **nmol/L**, the assay counts particle number and is far less affected by isoform. Current guidance from the European Atherosclerosis Society and the National Lipid Association favors nmol/L reporting.

Critically, there is no reliable conversion factor between the two. The often-cited "multiply by 2.4" or "divide by 2.5" shortcut can be off by a wide margin in either direction, because the true ratio depends on your personal isoform. If you retest, use the same lab and the same unit, and never convert one to the other to decide whether your value changed.

Reading the number: continuous risk, not a pass or fail line

Standard reporting flags under 30 mg/dL (roughly under 75 nmol/L) as low. But risk does not switch on at a threshold. It rises in a roughly continuous, dose-dependent way as the value climbs, with the steepest concern generally above 50 mg/dL (about 125 nmol/L) and markedly elevated risk above roughly 180 mg/dL (about 430 nmol/L), a level that European guidance from the ESC and the European Atherosclerosis Society equates with the lifetime cardiovascular burden of untreated heterozygous familial hypercholesterolemia.

The causal case is unusually strong. Large Mendelian randomization analyses from the Copenhagen City Heart and Copenhagen General Population studies (Kamstrup, Nordestgaard and colleagues) showed that genetically determined high Lp(a) predicts myocardial infarction, and Clarke et al. (New England Journal of Medicine, 2009) linked LPA variants to coronary disease in the PROCARDIS cohort. Genetics, not confounding, drives the association, which is why the marker is so trustworthy.

Lp(a) is also a leading causal risk factor for calcific aortic valve stenosis. Thanassoulis et al. (New England Journal of Medicine, 2013) tied an LPA genetic variant to aortic valve calcification, a link no LDL marker shows as cleanly. If your Lp(a) is high, valve health over the decades, not just coronary risk, is on the table.

What moves Lp(a), including one counterintuitive effect

Because roughly 80 to 90 percent of the variance is genetic, diet, exercise, and weight loss barely move Lp(a). A few things shift it, and one surprises people:

- **Statins can modestly raise Lp(a)**, on the order of 10 to 20 percent (Tsimikas and colleagues, meta-analysis of statin trials). Statins remain first-line for lowering ApoB, but they do not lower Lp(a) and may nudge it up. - **PCSK9 inhibitors** (evolocumab, alirocumab) lower it roughly 25 to 30 percent. - **Niacin** lowers it around 25 percent but failed to improve outcomes in the AIM-HIGH and HPS2-THRIVE trials, so it is not used for this purpose. - **Estrogen**, including oral menopausal hormone therapy, tends to lower Lp(a), while menopause, hypothyroidism, and worsening kidney function tend to raise it. - **Lipoprotein apheresis** is the only currently approved intervention that acutely and substantially lowers Lp(a), reserved for very high-risk patients.

The therapies to watch, and how tracking fits

The near future of Lp(a) is RNA-based. Pelacarsen, an antisense oligonucleotide in the Lp(a)HORIZON outcomes trial, and olpasiran, a siRNA agent (O'Donoghue et al., New England Journal of Medicine, 2022, OCEAN(a) program), both cut Lp(a) by roughly 80 to more than 90 percent. Lepodisiran is another siRNA in trials, and muvalaplin (Nissen and colleagues, JAMA) is the first oral small molecule, blocking assembly of the particle. None is approved on the basis of outcomes yet, and whether lowering the number lowers events is exactly the question these trials are built to answer.

For tracking, the practical model is simple. Lp(a) is a **one-time genetic input, not a protocol dial**. Peptide, growth hormone, and TRT protocols do not meaningfully move it, so there is no reason to retest it on a protocol schedule. Log the baseline value once, record the units and the lab, and let it inform how aggressively you and your clinician target the things that do move, especially ApoB, which you can track serially over time. A high Lp(a) will not change on your dashboard. What it changes is the target lines you draw around everything else. Discuss any elevated result and its management with your clinician.

Related Reading

• Apob Cardiovascular Risk Peptides →

Conditions That Track Lp(a)

Frequently Asked Questions

Where This Fits in Your Panel

Lp(a) is one marker on a fuller panel. The Peptide Blood Work Checklist lays out the complete baseline panel, what to add by protocol type, and when to retest.

Upload any lab PDF and MyProtocolStack maps your values to Lp(a) and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.